WTD Publishes New Resources Recommending MTHFR Should Be Removed From Thrombophilia Testing Panels
October 10th, 2022
The World Thrombosis Day (WTD) Scientific Steering Committee has released new important resources on thrombophilia testing and the MTHFR gene polymorphism. MTHFR stands for methylenetrahdrofolate reductase.
MTHFR polymorphisms are not an inherited thrombophilia, therefore the WTD Steering Committee recommends that they should not be included as part of a thrombophilia panel. Furthermore, patients who have these polymorphism should be reassured that this common finding does not place them at increased thrombotic risk and they do not, in fact, carry a thrombophilia. It is time for thrombosis experts to partner with patients and their laboratories and remove MTHFR polymorphism testing from existing thrombophilia panels, as is recommended by multiple professional societies and leading institutions. This will prevent unnecessary anxiety for patients and reduce healthcare spending.
Earlier this year, the WTD Steering Committee published a call-to-action paper on this topic, "A call to action: MTHFR polymorphisms should not be a part of inherited thrombophilia testing," published in Research and Practice in Thrombosis and Haemostasis (RPTH).
Watch and read the following new educational resources to learn more: